PL2654778T3 - Szczepionki oparte na peptydach białka dopełniacza C5A - Google Patents

Szczepionki oparte na peptydach białka dopełniacza C5A

Info

Publication number: PL2654778T3
Authority: PL; Poland
Prior art keywords: peptides; complement protein; vaccines based; vaccines; complement
Prior art date: 2010-12-21

Application number

PL11802093T

Other languages

English (en)

Inventor

Günther STAFFLER

Christine Landlinger

Frank Mattner

Original Assignee

Affiris Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-21

Filing date

2011-12-21

Publication date

2019-09-30

2011-12-21 Application filed by Affiris Ag filed Critical Affiris Ag

2019-09-30 Publication of PL2654778T3 publication Critical patent/PL2654778T3/pl

Links

102000000989 Complement System Proteins Human genes 0.000 title 1
108010069112 Complement System Proteins Proteins 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Zoology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)

PL11802093T 2010-12-21 2011-12-21 Szczepionki oparte na peptydach białka dopełniacza C5A PL2654778T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10196232A EP2468295A1 (en)	2010-12-21	2010-12-21	Vaccines based on peptides of the complement protein C5a
EP11802093.2A EP2654778B1 (en)	2010-12-21	2011-12-21	Vaccines based on peptides of the complement protein c5a
PCT/EP2011/073599 WO2012085090A1 (en)	2010-12-21	2011-12-21	Vaccines based on peptides of the complement protein c5a

Publications (1)

Publication Number	Publication Date
PL2654778T3 true PL2654778T3 (pl)	2019-09-30

Family

ID=43929080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11802093T PL2654778T3 (pl)	2010-12-21	2011-12-21	Szczepionki oparte na peptydach białka dopełniacza C5A

Country Status (16)

Country	Link
US (1)	US9457078B2 (pl)
EP (2)	EP2468295A1 (pl)
JP (1)	JP6016803B2 (pl)
KR (1)	KR20140053816A (pl)
CN (1)	CN103269711B (pl)
BR (1)	BR112013011285A2 (pl)
CA (1)	CA2822266A1 (pl)
DK (1)	DK2654778T3 (pl)
ES (1)	ES2718632T3 (pl)
IL (1)	IL225671A0 (pl)
MX (1)	MX2013007007A (pl)
NZ (1)	NZ608889A (pl)
PL (1)	PL2654778T3 (pl)
RU (1)	RU2013133875A (pl)
SG (1)	SG189842A1 (pl)
WO (1)	WO2012085090A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6876601B2 (ja) *	2014-07-10	2021-05-26	アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓＡｇ	ハンチントン病の予防および／または処置における使用のための物質および方法
CN116731149B (zh) *	2023-06-07	2024-02-27	华中农业大学	草鱼补体活化分子碳末端肽C5a-CP及应用
CN119019569B (zh) *	2024-08-19	2025-10-24	中国人民解放军陆军军医大学	一种可定向增强胸腺新生t细胞杀伤乳腺癌的多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4686100A (en)	1985-04-02	1987-08-11	The Board Of Trustees Of The Leland Stanford Junior University	Method for the treatment of adult respiratory distress syndrome
DE3785967T2 (de)	1986-04-28	1993-12-02	Cetus Corp	Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung.
CA2045578A1 (en) *	1989-01-31	1990-08-01	Megumi Kawai	Anaphylatoxin-receptor ligands
US5807824A (en)	1993-12-06	1998-09-15	Ciba-Geigy Corporation	C5A receptor antagonists having substantially no agonist activity
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JPH08109200A (ja)	1994-08-19	1996-04-30	Takeda Chem Ind Ltd	抗Ｃ５ａレセプター抗体、その製造法および用途
US5696230A (en)	1994-08-31	1997-12-09	The Board Of Regents Of The University Of Nebraska	High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
JPH11507215A (ja) *	1995-06-05	1999-06-29	ノバルティス・アクチエンゲゼルシャフト	アゴニスト活性を実質的にもたないＣ５ａ受容体アンタゴニストおよび製造方法
AUPO755097A0 (en)	1997-06-25	1997-07-17	University Of Queensland, The	Receptor agonist and antagonist
US6673346B1 (en) *	1999-08-31	2004-01-06	The Regents Of The University Of Michigan	Compositions and methods for the treatment of sepsis
MXPA04001301A (es)	2001-08-17	2004-07-08	Tanox Inc	Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
EP1878441B1 (en)	2001-08-17	2018-01-24	Genentech, Inc.	Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
US8071096B2 (en)	2002-01-25	2011-12-06	G2 Therapies Ltd	Anti-C5aR antibodies and uses thereof
ITMI20021527A1 (it) *	2002-07-11	2004-01-12	Consiglio Nazionale Ricerche	Anticorpi anti componente c5 del complemento e loro uso
EP1545611B1 (en)	2002-09-06	2016-11-09	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component c5
MXPA05005909A (es) *	2002-12-02	2005-08-26	Resistentia Pharmaceuticals Ab	Metodos y materiales para el tratamiento de condiciones inflamatorias usando un polipeptido que contiene un segmento aminoacido propio cs y un segmento aminoacido no propio.
HUE050481T2 (hu) *	2004-02-12	2020-12-28	Archemix Llc	Aptamer terapeutikumok, amelyek használhatók komplementtel kapcsolatos rendellenességek kezelésében
JP2006151866A (ja)	2004-11-29	2006-06-15	Canon Inc	フェナントロリン化合物及び発光素子
EP1861114B1 (en)	2005-03-11	2011-02-02	Potentia Pharmaceuticals, Inc.	Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration
JP2008543810A (ja)	2005-06-14	2008-12-04	サイトスバイオテクノロジーアーゲー	抗原コンジュゲート及びその使用
US20110092446A1 (en) *	2007-07-20	2011-04-21	Cedric Francois	Compositions and methods for treatment of trauma
CA2714296A1 (en)	2008-02-20	2009-08-27	G2 Inflammation Pty Ltd	Humanized anti-c5ar antibodies
AU2011245117B2 (en) *	2010-04-30	2015-03-12	Alexion Pharmaceuticals, Inc.	Anti-C5a antibodies and methods for using the antibodies

2010
- 2010-12-21 EP EP10196232A patent/EP2468295A1/en not_active Withdrawn
2011
- 2011-12-21 CN CN201180061862.XA patent/CN103269711B/zh not_active Expired - Fee Related
- 2011-12-21 WO PCT/EP2011/073599 patent/WO2012085090A1/en not_active Ceased
- 2011-12-21 CA CA2822266A patent/CA2822266A1/en not_active Abandoned
- 2011-12-21 NZ NZ608889A patent/NZ608889A/en not_active IP Right Cessation
- 2011-12-21 EP EP11802093.2A patent/EP2654778B1/en not_active Not-in-force
- 2011-12-21 ES ES11802093T patent/ES2718632T3/es active Active
- 2011-12-21 RU RU2013133875/10A patent/RU2013133875A/ru not_active Application Discontinuation
- 2011-12-21 MX MX2013007007A patent/MX2013007007A/es not_active Application Discontinuation
- 2011-12-21 BR BR112013011285A patent/BR112013011285A2/pt not_active IP Right Cessation
- 2011-12-21 DK DK11802093.2T patent/DK2654778T3/en active
- 2011-12-21 KR KR1020137013674A patent/KR20140053816A/ko not_active Withdrawn
- 2011-12-21 PL PL11802093T patent/PL2654778T3/pl unknown
- 2011-12-21 US US13/879,740 patent/US9457078B2/en not_active Expired - Fee Related
- 2011-12-21 JP JP2013545364A patent/JP6016803B2/ja not_active Expired - Fee Related
- 2011-12-21 SG SG2013025804A patent/SG189842A1/en unknown
2013
- 2013-04-10 IL IL225671A patent/IL225671A0/en unknown

Also Published As

Publication number	Publication date
SG189842A1 (en)	2013-06-28
EP2468295A1 (en)	2012-06-27
US20130216565A1 (en)	2013-08-22
DK2654778T3 (en)	2019-04-15
WO2012085090A1 (en)	2012-06-28
ES2718632T3 (es)	2019-07-03
AU2011347341B2 (en)	2016-05-12
AU2011347341A1 (en)	2013-05-02
RU2013133875A (ru)	2015-01-27
CA2822266A1 (en)	2012-06-28
KR20140053816A (ko)	2014-05-08
JP2014501745A (ja)	2014-01-23
MX2013007007A (es)	2013-07-29
US9457078B2 (en)	2016-10-04
CN103269711A (zh)	2013-08-28
BR112013011285A2 (pt)	2019-09-24
AU2011347341A8 (en)	2016-06-16
EP2654778B1 (en)	2019-01-23
CN103269711B (zh)	2016-06-08
NZ608889A (en)	2014-05-30
IL225671A0 (en)	2013-06-27
EP2654778A1 (en)	2013-10-30
JP6016803B2 (ja)	2016-10-26

Publication	Publication Date	Title
IL230918A0 (en)	2014-03-31	Modified proteins and peptides
GB201012651D0 (en)	2010-09-15	Peptides
SG11201500111VA (en)	2015-03-30	Peptides and uses thereof
EP2661442A4 (en)	2014-08-20	MONOMER AND MULTIMERS IMMUNOGENIC PEPTIDES
EP2605786A4 (en)	2014-03-12	THERAPEUTIC PEPTIDES
EP2593595A4 (en)	2014-03-26	NOVEL PEPTIDES AND USES THEREOF
EP2892913A4 (en)	2017-01-18	Peptides and their uses
EP3087093A4 (en)	2017-09-27	Pharmaceutically relevant aromatic-cationic peptides
IL245924A0 (en)	2016-07-31	topk peptides and components comprising them
ZA201207416B (en)	2013-06-26	Cdca5 peptides and vaccines including the same
EP2825548A4 (en)	2016-02-24	MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
IL228995A0 (en)	2013-12-31	b5sema peptides and components containing them
IL236690A0 (en)	2015-02-26	ube2t peptides and components containing them
PL3346273T3 (pl)	2023-04-11	Nowe, pochodzące od d3 d-enancjomeryczne peptydy i ich zastosowanie
IL238627B (en)	2018-12-31	Peptides containing a sequence derived from fviii
ZA201303886B (en)	2014-03-26	Tomm34 peptides and vaccines including the same
IL225671A0 (en)	2013-06-27	Vaccines based on complement c5a protein peptides
IL221474A0 (en)	2012-10-31	Hjurp peptides and vaccines including the same
GB201220899D0 (en)	2013-01-02	CD44v6-derived pegylated peptides
EP2521787A4 (en)	2013-11-13	IMPROVED PROTEIN EXPRESSION
IL238788A0 (en)	2015-06-30	sema5b peptides and components containing them
IL225552A0 (en)	2013-06-27	wdhd1 peptides and vaccines containing them
IL225553A0 (en)	2013-06-27	54orf18c peptides and vaccines containing them
GB201121236D0 (en)	2012-01-18	Proteins and peptides
GB201010058D0 (en)	2010-07-21	Peptide vaccine